A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain. Our Strategy Our goal is to build a fully-integrated and profitable biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics to treat a range of neurological and psychiatric disorders.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | 0 | - | - |
| Net Income | -346M | -346M | -234M | -182M | -125M | -77M |
| EPS | $-4.36 | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 |
| Free Cash Flow | -280M | -280M | -184M | -157M | -101M | -72M |
| ROIC | -75.5% | -51.8% | -31.0% | -22.2% | -17.1% | -13.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.01 | - | - | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -373M | -373M | -279M | -214M | -129M | -79M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -59.5% | -51.8% | -31.0% | - | - | - |
| Shares Outstanding | 79M | 79M | 78M | 67M | 61M | 44M |
Xenon Pharmaceuticals Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Xenon Pharmaceuticals Inc. (XENE) has a 5-year average return on invested capital (ROIC) of -27.2%. This is below average and may indicate limited pricing power.
Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $4.6B. It is classified as a mid-cap stock.
Xenon Pharmaceuticals Inc. (XENE) does not currently pay a regular dividend.
Xenon Pharmaceuticals Inc. (XENE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Xenon Pharmaceuticals Inc. (XENE) generated $-280 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Xenon Pharmaceuticals Inc. (XENE) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Xenon Pharmaceuticals Inc. (XENE) reported earnings per share (EPS) of $-4.36 in its most recent fiscal year.
Xenon Pharmaceuticals Inc. (XENE) has a return on equity (ROE) of -51.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for Xenon Pharmaceuticals Inc. (XENE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Xenon Pharmaceuticals Inc. (XENE) has a book value per share of $7.33, based on its most recent annual SEC filing.